SCHEMBL14740374

SCHEMBL14740374

O=c1[nH]ccc2c1CC(=S)N2Cc1ccc2[nH]ccc2c1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.39
MAPT P10636 1/20 0.39
FAAH O00519 1/20 0.38
HCRTR1 O43613 1/20 0.37
HCRTR2 O43614 1/20 0.37
DRD4 P21917 1/20 0.36
SIGMAR1 Q99720 1/20 0.36
PARP1 P09874 2/20 0.36
PARP2 Q9UGN5 1/20 0.36
CYP17A1 P05093 1/20 0.34
CYP11B1 P15538 1/20 0.34
CYP11B2 P19099 1/20 0.34
CYP19A1 P11511 1/20 0.34
F7 P08709 1/20 0.34
LTA4H P09960 1/20 0.34
F3 P13726 1/20 0.34
AHR P35869 1/20 0.34
NR4A2 P43354 1/20 0.34
HDAC1 Q13547 1/20 0.34
HDAC8 Q9BY41 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14740128 0.92 BACE1 (0.37) KDM4EFAAHPARP1AHRMCHR1
SCHEMBL1536813 0.72 MPO (0.46)
SCHEMBL14739742 0.72 ALOX15 (0.41) PARP1
SCHEMBL14739684 0.71 CYP1B1 (0.37) MAPT
SCHEMBL21632680 0.71 CYP17A1 (0.39) KDM4EMAPTFAAHHCRTR1HCRTR2
SCHEMBL14740299 0.71 BCHE (0.46) KDM4EMAPTDRD4AHR
SCHEMBL1162212 0.69 GSK3A (0.52) KDM4EMAPTFAAHHCRTR1HCRTR2
SCHEMBL1162209 0.69 HCRTR1 (0.43) KDM4EMAPTFAAHHCRTR1HCRTR2
SCHEMBL1536595 0.65 MPO (0.52) KCNH2
SCHEMBL13293706 0.64 FAAH (0.55) KDM4EFAAHDRD4SIGMAR1LTA4H

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150099769-A1 PYRROLO[3,2-D]PYRIMIDIN-4-ONE DERIVATIVES AND THEIR USE IN THERAPY ASTRAZENECA AB (SE) 2015-04-09 US claimed
US-20130059870-A1 USE OF MYELOPEROXIDASE (MPO) INHIBITORS OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF TO TREAT MULTIPLE SYSYEM ATROPHY (MSA) 938 ASTRAZENECA AB (SE) 2013-03-07 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150099769-A1 PYRROLO[3,2-D]PYRIMIDIN-4-ONE DERIVATIVES AND THEIR USE IN THERAPY MPO, EPX, XDH KDM4E 2619/4885MAPT 4038/4885FAAH 1353/4885
US-20130059870-A1 USE OF MYELOPEROXIDASE (MPO) INHIBITORS OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF TO TREAT MULTIPLE SYSYEM ATROPHY (MSA) 938 MPO, CAT, HTT KDM4E 1452/4885MAPT 136/4885FAAH 1052/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.